Calcineurin Inhibitors Replacement by Ruxolitinib as Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation

Severe graft versus host disease (GVHD) is a leading cause of morbidity and mortality after allogeneic stem cell transplantation (allo-SCT). Currently, the most widely used prophylaxis regimen usually consists of calcineurin inhibitor (CNI; i.e., tacrolimus and cyclosporine) plus methotrexate (MTX) and/or mycophenolate mofetil (MMF) [1-5]. However, the incidence of acute GVHD (aGVHD) is about 30% –50%, and CNI can also inhibit the graft-versus-leukemia (GVL) effect while reducing aGVHD, thereby increasing the relapse rate.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research